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Figure S1. Spearman correlations between neutralization profiles of C117 and C110 
plasma isolates and neutralization profiles of bNAbs HEPC3, HEPC74, HEPC43, and 
CBH-2, related to Figure 1. Neutralization profiles were defined using a panel of nineteen 
genotype 1 HCVpp. Each point indicates neutralization of a single HCVpp strain by the 
indicated mAb on the x-axis, and the indicated plasma sample on the y-axis. Spearman 
correlations (r) and two-sided p values are indicated for each comparison. (A) C117 plasma with 
autologous bNAb HEPC3. (B) C110 plasma with autologous bNAbs HEPC74 (top) and HEPC43 
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Figure S2. Highlighter plot 
indicating positions of amino 
acid differences in longitudinal 
viral sequences obtained by 
single-genome amplification 
from plasma of three subjects at 
time points throughout the 
course of infection, related to 
Figure 2. Amino acid differences 
from a master sequence are 
indicated by colored bars. 
Sequences are arranged by their 
date of isolation. Proteins are 
indicated, and hypervariable region 
1 (HVR1) is highlighted in red. 
Numbering is relative to strain H77 
polyprotein. (A) Full genome 
analysis of C117 infection. Amino 
acid changes relative to D17-1a53 
(T/F#3) are identified. The 
sequence of the final circulating 
viral strain present immediately 
prior to clearance of infection was 
amplified in separate 5  and 3
hemigenomic reactions. (B) 5
hemigenomic analysis of C110 
infection. Amino acid changes 
relative to both D0-A4 (Infxn 1) 
and Bole1a are identified. (C) 5  
hemigenomic analysis of P29 
infection. Amino acid changes 










































Infxn 1 vs. Infxn 1
Infxn 2 vs. Infxn 2
Infxn 3 vs. Infxn 3
Infxn 1 vs. Infxn 2
Infxn 1 vs. Infxn 3



















Figure S3. C110 cleared three genetically distinct genotype 1a infections, related to Figure 
2. (A) Maximum likelihood phylogenetic tree of 5 kb hemigenomic nucleotide sequences 
obtained by single-genome amplification from plasma of C110 at longitudinal time points 
throughout the course of infection, with Bole1a and strain H77 as outgroups. Bootstrap values 
greater than 90 are shown. Genetically distinct infections are highlighted in different colors, with 
days post initial infection at the time of sampling indicated. (B) Pairwise genetic distances 
between 374 genotype 1a unrelated 5′ nucleotide hemigenomes from GenBank, and between the 
indicated groups of C110 sequences. 



















































































D17-1a53 N H F P D D
D17-SDM1 · · · · · H
D17-SDM2 D · · · · H
D17-SDM3 D · Y · · H
D17-SDM4 D · Y · V H
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mutations introduced
Figure S4. Site-directed mutagenesis identifies E2 substitutions responsible for partial 
resistance to HEPC3 binding or HEPC43 and HEPC74 neutralization, related to Figures 3-
4. (A) Binding of serial dilutions of HEPC3 to E1E2 proteins in an ELISA. E1E2 strains tested 
include C117 D17-1a53 as well as this strain after introduction of the substitutions shown using 
site-directed mutagenesis (D17-SDM 1-5). One experiment representative of two independent 
experiments is shown. (B) Neutralization by C110 D436 plasma (top) HEPC43 (middle) or 
HEPC74 (bottom) of HCVpp expressing D0-A4 E1E2, or that strain after introduction of the 
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Figure S5. Second independent experiments: naturally selected substitutions in C117 or 
C110 E2 confer partial resistance to autologous plasma antibodies and autologous bNAbs, 
related to Figure 3-4. (A-C) Binding to longitudinal C117 E1E2 proteins (left) or neutralization 
of longitudinal C117 HCVpp (right) by C117 D388 plasma IgG (A), HEPC3 (B) or HEPC98 
(C). (D) Neutralization of longitudinal C110 HCVpp from Infxn 1 and 2 by C110 D436 plasma. 
(E)  Neutralization of P29 HCVpp by P29 D416 plasma. All assays were performed in duplicate, 
and values are means +/- SD. 













































Figure S6. Second independent experiment: infectivity of serial dilutions of chimeric 1 
replication competent cell culture virus (HCVcc) expressing longitudinal (A) C117 or (B) 2 
C110 E1E2 strains, measured as focus forming units/mL (FFU/mL) in Huh7.5.1 cells 48 3 
hours after inoculation, related to Figure 5. Values are normalized for input HCV viral copy 4 
number. Assays were performed in duplicate, and values are means +/- SD. 5 



































































































Figure S7. Relative quantitation of E1E2 and sE2 proteins, related to Figures 3 and 6. (A) 
Lysates of cells transfected with E1E2 expression plasmids were used to coat ELISA wells, then 
incubated with serial dilutions of control bNAb HC33.4. This bNAb binds to a linear, non-
conformational epitope that is intact in all strains, so level of binding is proportional to the 
protein concentration. (B-E) Serial dilutions of sE2 supernatants were plated in ELISA wells and 
detected with anti-His antibody. Relative protein concentration in different supernatants were 
estimated from relative EC50 values of anti-His binding, and supernatants were adjusted to 
equivalent sE2 concentrations prior to CD81 and SR-B1 binding experiments. (B) C117 natural 
sE2 strains. (C) C117 SDM sE2 strains. (D) C110 natural sE2 strains. (E) C110 SDM sE2 
strains. 
Table S1. HCV substitutions arising over the course of C117, C110, and P29 infections. 
Changes away from (black text) or toward (blue text) the Bole1a sequence are indicated. *Only 
changes away from Bole1a are shown. Related to Fig 2. 
   E2  
Subject Viral strains 
compared  
Core-E1 HVR1 front layer E2 (other) P7-NS5B 
C117 D17-1a53 T/F#3 → 
D388-5A12 
  G390D N434D F465Y H2030Q 
Q391R H444Y P498S N2633S 
Y394R   D533N R2720Q 
T395A   D610H   
L402F       
T404N       
C110   D0-A4 (Infxn1) → 
D178-A31 T/F#5 
(Infxn 2)* 
A217D E384K L438I R461L I753V 
V242I H386Y F442I A466D K781R 
D303G V387T N445H A475T T812A 
L345V T388S   V570D A828V 
  G401S   I622V R837N 
  P405S   E641D L876I 
      D653N I938L 
        P978R 
        K1250Q 
        P1290S 
        V1384A 
        K1398R 
        L1410M 
        F1583L 
        I1641V 
C110   D178-A31 T/F#5 → 
D436-C22 (Infxn 2 
only) 
  K384G     F849L 
  T387I     M936V 
  A397S     V1408G 
  F399L       
  A400V       
  F403L       
  S405P       
C110  D0-A4 (Infxn 1) → 
D1260-B3 (Infxn 3)* 
A217D E384G N434K D464K I753V 
V242I H386Y N445H A475T K781R 
D303G T388S   P498A T812A 
L345M S391A   K500Q A828V 
  A400V   E531V R837S 
  F403L   V570D Y838H 
  S404A   T577D F849L 
      S595A M928I 
      I622V I938L 
      E641D T945A 
        P978R 
        I1044V 
        P1290S 
        V1384A 
        L1410M 
        A1503T 
        F1583L 
        P1600L 
        I1641V 
C110  D1260-B3 → 
D1875-C3  
(Infxn 3 only) 
  Y386H   T463V K1250R 
  G398R       
P29  D16-B11 T/F#1 → 
D416-A26 
      T463N N958D 























































































































































           X 
P,S405  
           X 
K,S408  
           X 
I414 X  
           
N417 X  
           
G418 X  
           
S419 X  
           
W420           X   
H421   X           
I422           X   
S,R424     X X X     
T425     X X X X   
L427 X X X X X X   
N428 X   X X X X   
C429 X   X X X X   
N430 X X           
E,D431 X X           
N,H434 X X   X       
T435 X X           
G436 X X X X X     
W,F437   X X X X X   
L438 X X X X X X   
A439 X X           
G,A440 X X X     X   
L441     X   X X   
F442 X X X     X   
Y443 X X       X   
H445   X           
K446 X X           
F447 X X           
D448 X X           
R455       X       
A499     X X X     
C503     X X X X   
V515       X X     
G517     X         
T518     X X X X   
T519       X X     
D520     X X X X   
G523       X X     
Y527           X   
W529 X X X     X   
G530     X X X     
A,E531 X X           
D535     X X X X   
W616     X X   X   
C620           X   
I626         X     
T647         X     
Table S2. E2-contact and/or 
critical binding residues of 
HEPC3, HEPC74, HEPC43, 
HEPC98, and CD81LEL. 
Positions identiﬁed as contact 
residues displayed > 10 Å2 of 
buried surface area in the bNAb-
1b09ecto complex crystal structure. 
Binding residues for bNAbs and 
CD81LEL were identiﬁed by 
alanine scanning as described in 
Methods. Red: Contact and/or 
binding residues shared by any 
bNAb and CD81LEL. Related to 
Fig 7. 
Table S3. T cell interferon gamma responses to overlapping peptides spanning the entire HCV 
polyprotein. Related to Fig 2. 
Subject Days post-
infection 




Sequence recognized (# aa) 
C117 46 No detectable T cell responses 
110 No detectable T cell responses 
194 No detectable T cell responses 
285 No detectable T cell responses 
C110 912 No detectable T cell responses 
1009 No detectable T cell responses 
1267 1169-1177 NS3 LLCPAGHAV (9) 
1267 1243-1258 NS3 AYAAQGYKVLVLNPSV 
(16) 
1267 1983-1998 NS5A WICEVLSDFKTWLKAK 
(16) 
1267 1987-1995 NS5A VLSDFKTWL (9) 
1267 2526-2539 NS5B KDVRCHARKAVAHI (14) 
1267 2903-2918 NS5B NRVAACLRKLGVPPLR 
(16) 
P29 58 1073-1081 NS3 CINGVCWTV (9) 
114 1073-1081 NS3 CINGVCWTV (9) 
135 512-527 E2 SPVVVGTTDRSGAPTY 
(16) 
135 1073-1081 NS3 CINGVCWTV (9) 
135 1395-1403 NS3 HSKKKCDEL (9) 
 
 
 
 
 
 
 
 
 
 
 
 
